Results 31 to 40 of about 898 (129)

The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers [PDF]

, 2014
The primary constituents of plaques (Aβ42/Aβ40) and neurofibrillary tangles (tau and phosphorylated forms of tau [ptau]) are the current leading diagnostic and prognostic cerebrospinal fluid (CSF) biomarkers for AD.
Benitez, Bruno A., Bennett, David A., Bertelsen, Sarah, Cai, Yefei, Carrell, David, Chibnik, Lori, Cooper, Breanna, Cruchaga, Carlos, Fagan, Anne M., Goate, Alison M., Holtzman, David, Jin, Sheng Chih, Karch, Celeste M., Morris, John C., Schneider, Julie A.   +14 more
core   +1 more source

Associations of apolipoprotein E exon 4 and lipoprotein lipase S447X polymorphisms with acute ischemic stroke and myocardial infarction [PDF]

, 2006
Background: Because apolipoprotein E (apoE) and lipopoprotein lipase (LPL) polymorphisms interact with each other and with other factors to affect lipid metabolism, we sought to determine their separate and combined effects in association with ischemic ...
Baum, L, Chan, DKY, Chen, X, Chook, P, Goggins, W, Ho, KN, Ka, SW, Kam, SW, Rainer, TH, Tam, WWS, Tang, J, Thomas, GN, Tomlinson, B, Tong, CSW, Wing, SC   +14 more
core   +1 more source

Systematic review and network meta-analysis on the efficacy of evolocumab and other therapies for the management of lipid levels in hyperlipidemia [PDF]

, 2017
Background: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors evolocumab and alirocumab substantially reduce low‐density lipoprotein cholesterol (LDL‐C) when added to statin therapy in patients who need additional LDL‐C reduction ...
Bray, Sarah, Bridges, Ian, Cheng, Lung-I, Dent, Ricardo, Deshpande, Sohan, Forbes, Carol A., Gandra, Shravanthi R., Kleijnen, Jos, Ross, Janine, Sattar, Naveed, Stroes, Erik S.G., Toth, Peter P., Worth, Gavin M., Worthy, Gillian   +13 more
core   +1 more source

Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial [PDF]

, 2017
Aims High-density lipoprotein cholesterol (HDL-C) is inversely associated with cardiovascular (CV) events and thus an attractive therapeutic target. However, in spite of marked elevations in HDL-C, the first cholesterol transport protein (CETP) inhibitor
Deanfield, John E., Jukema, J. Wouter, Kallend, David, Kaski, Juan-Carlos, Kastelein, John J.P., Lüscher, Thomas F., Münzel, Thomas, Taddei, Stefano   +7 more
core  

The PSEN1, p.E318G variant increases the risk of Alzheimer’s disease in APOE-ԑ4 carriers [PDF]

, 2013
The primary constituents of plaques (Aβ42/Aβ40) and neurofibrillary tangles (tau and phosphorylated forms of tau [ptau]) are the current leading diagnostic and prognostic cerebrospinal fluid (CSF) biomarkers for AD.
Alzheimer’s Disease Neuroimaging Initiative (ADNI),, Benitez, Bruno A, Bennett, David A, Bertelsen, Sarah, Cai, Yefei, Carrell, David, Chibnik, Lori, Cooper, Breanna, Cruchaga, Carlos, Fagan, Anne M, Genetic and Environmental Risk for Alzheimer’s Disease Consortium (GERAD1),, Goate, Alison M, Holtzman, David, Jin, Sheng Chih, Karch, Celeste M, Morris, John C, Schneider, Julie A   +16 more
core   +4 more sources

Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin [PDF]

, 2017
The present study is the first intervention study in a well-established, translational mouse model for hyperlipidaemia and atherosclerosis showing that anacetrapib dose-dependently reduces atherosclerosis development and adds to the anti-atherogenic ...
Havekes, Louis M., Jukema, J. Wouter, Kühnast, Susan, Landmesser, Ulf, Lüscher, Thomas F., Pieterman, Elsbet, Princen, Hans M.G., Rensen, Patrick C.N., Simic, Branko, van der Hoorn, José W.A., van der Tuin, Sam J.L., van Klinken, Jan B., Willems van Dijk, Ko   +12 more
core  

The Year in Cardiology 2013: cardiovascular disease prevention [PDF]

, 2017
The decline in cardiovascular mortality in Europe by nearly 50% over the last three decades resulted in particular from improved risk factor control and prevention interventions in addition to improved treatment.
Gielen, S., Landmesser, U.
core  

Parameter adaptations during phenotype transitions in progressive diseases [PDF]

, 2011
Background The study of phenotype transitions is important to understand progressive diseases, e.g., diabetes mellitus, metabolic syndrome, and cardiovascular diseases.
Hilbers, Peter AJ, Tiemann, Christian A, van Riel, Natal AW, Vanlier, Joep   +3 more
core   +4 more sources

Therapeutic intranasal vaccine HB-ATV-8 prevents atherogenesis and non-alcoholic fatty liver disease in a pig model of atherosclerosis [PDF]

, 2018
BACKGROUND AND AIMS: Atherosclerosis as an inflammatory disease involved in the etiology of cardiovascular disease worldwide, in our days demands an array of different therapeutic approaches in order to soon be able to visualize an effective prevention ...
Calixto-Tlacomulco, S., Damián-Zamacona, S., Delgado-Coello, B., Gutiérrez-Vidal, R., Mas-Oliva, J., Méndez-Acevedo, K.M.   +5 more
core   +1 more source

Cholesteryl ester transfer protein inhibition for preventing cardiovascular events: JACC review topic of the week [PDF]

, 2019
Cholesteryl ester transfer protein (CETP) facilitates exchange of triglycerides and cholesteryl ester between high-density lipoprotein (HDL) and apolipoprotein B100–containing lipoproteins.
Armitage, Jane, Holmes, Michael V., Preiss, David   +2 more
core   +2 more sources